Journal of the Formosan Medical Association
Volume 108, Issue 5 , Pages 423-427, May 2009

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Received 12 March 2008; received in revised form 11 September 2008; accepted 24 September 2008.

Article Outline

The immunomodulating effect of human leukocyte antigen (HLA)-DR and the central role of CD4 T cells in alloimmunity provide clues suggesting that HLA-DR-matched, partially mismatched related donors could be feasible alternative donors of allogeneic hematopoietic stem cells for transplantations (allo-HSCT). We describe our experience with allo-HSCT in eight patients with high-risk acute leukemia; donors included one of each of the parents. Among the eight patients, seven were identical HLA-DR matches with the donors. The stem cells were not manipulated in vitro. Graft-versus-host disease (GVHD) prophylaxis consisted of antithymocyte globulin, cyclosporine, and methotrexate. All patients had successful trilineage engraftment. Only one patient had grade 2–4 acute GVHD. Two patients died before day +100 due to complications. At the end of follow-up, four patients had survived for 18–48 months and three are alive and without relapse. Our results suggest that HLA-DR fully-matched parents are feasible alternative donors for allo-HSCT in patients with high-risk acute leukemia under an intensive conditioning regimen.

Key Words:  allogeneic hematopoietic stem cell transplantation , HLA-DR , parental donors

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Appelbaum FR . Allogeneic hematopoietic stem cell transplantation for acute leukemia . Semin Oncol . 1997;24:114–123
  2. Thomas ED . Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases . J Clin Oncol . 1983;1:517–531
  3. Henslee-Downey PJ . Mismatched bone marrow transplantation . Curr Opin Oncol . 1995;7:115–121
  4. Beatty PG , Clift RA , Mickelson EM , et al.   Marrow transplantation from related donors other than HLA-identical siblings . N Engl J Med . 1985;313:765–771
  5. Anasetti C , Amos D , Beatty PG , et al.   Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma . N Engl J Med . 1989;320:197–204
  6. Lechler R , Warrens A . HLA and transplantation I: allorecognition of HLA molecules in transplantation . HLA in Health and Disease . 2nd edition. Academic Press; 2000;
  7. Middleton D , Martin J , Douglas J , et al.   Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft . Transplantation . 1994;58:845–848
  8. Lagaaij EL , Hennemann IP , Ruigrok M , et al.   Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts . N Engl J Med . 1989;321:701–705
  9. Waanders MM , Roelen DL , Brand A , et al.   The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response . Transfus Med Rev . 2005;19:281–287
  10. Osarogiagbon RU , Defor TE , Weisdorf MA , et al.   CMV antigenemia following bone marrow transplantation: risk factors and outcomes . Biol Blood Marrow Transplant . 2000;6:280–288
  11. Kanda Y , Mineishi S , Saito T , et al.   Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan . Bone Marrow Transplant . 2001;27:437–444
  12. Doxiadis II , de Fijter JW , Mallat MJ , et al.   Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility . Transplantation . 2007;83:1207–1213

PII: S0929-6646(09)60087-5

doi:10.1016/S0929-6646(09)60087-5

Journal of the Formosan Medical Association
Volume 108, Issue 5 , Pages 423-427, May 2009

Article Tools